[go: up one dir, main page]

MX2018007204A - Identificacion, fabricacion y uso de neoantigeno. - Google Patents

Identificacion, fabricacion y uso de neoantigeno.

Info

Publication number
MX2018007204A
MX2018007204A MX2018007204A MX2018007204A MX2018007204A MX 2018007204 A MX2018007204 A MX 2018007204A MX 2018007204 A MX2018007204 A MX 2018007204A MX 2018007204 A MX2018007204 A MX 2018007204A MX 2018007204 A MX2018007204 A MX 2018007204A
Authority
MX
Mexico
Prior art keywords
methods
manufacture
systems
tumor
neoantigen identification
Prior art date
Application number
MX2018007204A
Other languages
English (en)
Inventor
Yelensky Roman
Derti Adnan
Bulik-Sullivan Brendan
Busby Jennifer
Original Assignee
Gritstone Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59057557&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018007204(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gritstone Oncology Inc filed Critical Gritstone Oncology Inc
Publication of MX2018007204A publication Critical patent/MX2018007204A/es

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/62—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
    • G01N33/5758—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09F—DISPLAYING; ADVERTISING; SIGNS; LABELS OR NAME-PLATES; SEALS
    • G09F19/00—Advertising or display means not otherwise provided for
    • G09F19/12—Advertising or display means not otherwise provided for using special optical effects
    • G09F19/16—Advertising or display means not otherwise provided for using special optical effects involving the use of mirrors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G16B50/40—Encryption of genetic data
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioethics (AREA)
  • Urology & Nephrology (AREA)

Abstract

Se describe en la presente un sistema y métodos para determinar los alelos, neoantígenos, y composición de vacuna como es determinado sobre la base de las mutaciones tumorales de un individuo. También se describen sistemas y métodos para obtener datos de secuenciación de alta calidad de un tumor. Además, se describen en la presente sistemas y métodos para identificar cambios somáticos en los datos de genoma polimórficos. Finalmente, se describen en la presente vacunas únicas contra el cáncer.
MX2018007204A 2015-12-16 2016-12-16 Identificacion, fabricacion y uso de neoantigeno. MX2018007204A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562268333P 2015-12-16 2015-12-16
US201662317823P 2016-04-04 2016-04-04
US201662379986P 2016-08-26 2016-08-26
US201662394074P 2016-09-13 2016-09-13
US201662425995P 2016-11-23 2016-11-23
PCT/US2016/067159 WO2017106638A1 (en) 2015-12-16 2016-12-16 Neoantigen identification, manufacture, and use

Publications (1)

Publication Number Publication Date
MX2018007204A true MX2018007204A (es) 2018-12-11

Family

ID=59057557

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018007204A MX2018007204A (es) 2015-12-16 2016-12-16 Identificacion, fabricacion y uso de neoantigeno.
MX2023014124A MX2023014124A (es) 2015-12-16 2018-06-13 Identificacion, fabricacion y uso de neoantigeno.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023014124A MX2023014124A (es) 2015-12-16 2018-06-13 Identificacion, fabricacion y uso de neoantigeno.

Country Status (18)

Country Link
US (7) US20170199961A1 (es)
EP (2) EP4299136A3 (es)
JP (3) JP7114477B2 (es)
KR (2) KR20250164855A (es)
CN (2) CN108601731A (es)
AU (2) AU2016369519B2 (es)
BR (1) BR112018012374A2 (es)
CA (1) CA3008641A1 (es)
CO (1) CO2018007417A2 (es)
ES (1) ES2970865T3 (es)
IL (3) IL322399A (es)
MX (2) MX2018007204A (es)
PE (1) PE20181535A1 (es)
PH (1) PH12018501267A1 (es)
RU (1) RU2729116C2 (es)
SG (1) SG11201804957VA (es)
TW (1) TWI765875B (es)
WO (1) WO2017106638A1 (es)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9128861B2 (en) 2013-01-17 2015-09-08 Personalis, Inc. Methods and systems for genetic analysis
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CN106456724A (zh) 2013-12-20 2017-02-22 博德研究所 使用新抗原疫苗的联合疗法
CN113791220A (zh) 2014-09-10 2021-12-14 豪夫迈·罗氏有限公司 免疫原性突变体肽筛选平台
US11338026B2 (en) 2014-09-10 2022-05-24 The University Of Connecticut Identification of immunologically protective neo-epitopes for the treatment of cancers
EP3212808B1 (en) 2014-10-30 2022-03-02 Personalis, Inc. Methods for using mosaicism in nucleic acids sampled distal to their origin
ES3049406T3 (en) 2014-12-19 2025-12-16 Broad Inst Inc Methods for profiling the t-cell-receptor repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
CN108601731A (zh) 2015-12-16 2018-09-28 磨石肿瘤生物技术公司 新抗原的鉴别、制造及使用
US11514289B1 (en) 2016-03-09 2022-11-29 Freenome Holdings, Inc. Generating machine learning models using genetic data
WO2017194170A1 (en) 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
US11299783B2 (en) 2016-05-27 2022-04-12 Personalis, Inc. Methods and systems for genetic analysis
EP3967324A1 (en) * 2016-07-20 2022-03-16 BioNTech SE Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy
CN106295678B (zh) * 2016-07-27 2020-03-06 北京旷视科技有限公司 神经网络训练与构建方法和装置以及目标检测方法和装置
EP3494231A4 (en) * 2016-08-02 2020-04-15 Georgetown University METHOD FOR IDENTIFYING NEW PROTEINS AND ANTIGENS IN CANCER CELLS
CN110214275B (zh) 2016-12-01 2022-12-06 南托米克斯有限责任公司 肿瘤抗原性加工和呈递
WO2018136664A1 (en) * 2017-01-18 2018-07-26 Ichan School Of Medicine At Mount Sinai Neoantigens and uses thereof for treating cancer
DK3580561T3 (da) 2017-02-12 2023-12-18 Biontech Us Inc Hla-baserede metoder, sammensætninger og anvendelse heraf
EP3568811B1 (en) * 2017-02-24 2024-10-16 DeepMind Technologies Limited Training machine learning models
US20210113673A1 (en) * 2017-04-19 2021-04-22 Gritstone Oncology, Inc. Neoantigen Identification, Manufacture, and Use
KR20200003390A (ko) 2017-05-08 2020-01-09 그릿스톤 온콜로지, 인코포레이티드 알파바이러스 신생항원 벡터
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
JP7334124B2 (ja) * 2017-06-21 2023-08-28 トランジェーヌ 個別化ワクチン
US12374423B2 (en) 2017-06-27 2025-07-29 The Broad Institute, Inc Systems and methods for MHC class II epitope prediction
EP3651791A1 (en) 2017-07-14 2020-05-20 The Francis Crick Institute Limited Analysis of hla alleles in tumours and the uses thereof
EP3658683A4 (en) * 2017-07-25 2021-04-21 California Institute of Technology DISCOVERY OF TROGOCYTOSIS-MEDIATED EPITOPIA
JP6928948B2 (ja) * 2017-08-09 2021-09-01 学校法人日本大学 口臭判定装置及びプログラム
JP7693189B2 (ja) * 2017-08-10 2025-06-17 グッド ティー セルズ、 インコーポレイテッド 癌治療のためのｔ細胞の活性化方法
JP7763588B2 (ja) * 2017-09-05 2025-11-04 グリットストーン バイオ インコーポレイテッド Ｔ細胞療法用の新生抗原の特定法
CN118888004A (zh) 2017-10-10 2024-11-01 磨石生物公司 使用热点进行的新抗原鉴别
US11861491B2 (en) 2017-10-16 2024-01-02 Illumina, Inc. Deep learning-based pathogenicity classifier for promoter single nucleotide variants (pSNVs)
SG10202108020VA (en) * 2017-10-16 2021-09-29 Illumina Inc Deep learning-based techniques for training deep convolutional neural networks
AU2018350909B2 (en) * 2017-10-16 2021-09-23 Illumina, Inc. Aberrant splicing detection using convolutional neural networks (CNNS)
CN111630602A (zh) * 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
CN109682978B (zh) * 2017-11-30 2020-07-03 四川康德赛医疗科技有限公司 一种肿瘤突变肽mhc亲和力预测方法及其应用
EP3735271A4 (en) 2018-01-04 2022-06-15 Iconic Therapeutics, Inc. ANTI-TISSUE FACTOR ANTIBODIES, ANTIBODY DRUG CONJUGATES AND RELATED METHODS
WO2019168984A1 (en) * 2018-02-27 2019-09-06 Gritstone Oncology, Inc. Neoantigen identification with pan-allele models
WO2019173687A1 (en) * 2018-03-08 2019-09-12 The Trustees Of Indiana University Constrained de novo sequencing of neo-epitope peptides using tandem mass spectrometry
WO2019200398A1 (en) * 2018-04-13 2019-10-17 Dana-Farber Cancer Institute, Inc. Ultra-sensitive detection of cancer by algorithmic analysis
KR102212663B1 (ko) * 2018-05-22 2021-02-05 주식회사 석영시스템즈 목표 온도를 기반으로 하는 빌딩의 열·공조 시스템에 대한 공급 전력 제어 방법 및 장치
CN112368386A (zh) * 2018-05-23 2021-02-12 磨石肿瘤生物技术公司 共有抗原
US11814750B2 (en) 2018-05-31 2023-11-14 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
US10801064B2 (en) 2018-05-31 2020-10-13 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
WO2020022898A2 (en) * 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Off-the-shelf cancer vaccines
EP3827262A1 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
AU2019330487B2 (en) * 2018-08-30 2025-04-03 Université de Montréal Proteogenomic-based method for identifying tumor-specific antigens
MX2021003654A (es) 2018-09-27 2021-05-28 Nykode Therapeutics AS Metodo para seleccionar neoepitopes.
US20210382068A1 (en) * 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20220088174A1 (en) * 2018-10-26 2022-03-24 Dana-Farber Cancer Institute, Inc. Genomic variants in ig gene regions and uses of same
WO2020092382A1 (en) * 2018-10-29 2020-05-07 Health Research, Inc. Cancer specific immunotherapeutic targets generated by chemotherapeutic drug treatment
JP7239300B2 (ja) * 2018-11-01 2023-03-14 浜松ホトニクス株式会社 スペクトル分析装置およびスペクトル分析方法
KR20210092723A (ko) * 2018-11-15 2021-07-26 노우스콤 아게 개인 맞춤형 암 백신 생성을 위한 암 돌연변이 선택
SG11202102582TA (en) 2018-11-21 2021-04-29 Nec Corp Method and system of targeting epitopes for neoantigen-based immunotherapy
US20220076783A1 (en) * 2018-12-20 2022-03-10 Merck Sharp & Dohme Corp. Methods and Systems for the Precise Identification of Immunogenic Tumor Neoantigens
EP4582440A3 (en) * 2018-12-21 2025-10-08 The Regents of the University of California Il-10-containing vaccines and uses thereof
BR112021012278A2 (pt) * 2018-12-21 2021-12-14 Biontech Us Inc Método e sistema para a preparação de células hla de classe ii-específica de epitopes e de síntese de cd4 + t
CN109712672B (zh) * 2018-12-29 2021-05-25 北京优迅医学检验实验室有限公司 检测基因重排的方法、装置、存储介质及处理器
CN109706065A (zh) * 2018-12-29 2019-05-03 深圳裕策生物科技有限公司 肿瘤新生抗原负荷检测装置及存储介质
AU2020204779B2 (en) 2019-01-03 2024-12-05 Evaxion Biotech A/S Vaccines targeting neoepitopes
CN110675913B (zh) * 2019-01-16 2022-04-12 倍而达药业（苏州）有限公司 一种基于hla分型与结构的肿瘤新抗原的筛选方法
CN109801678B (zh) * 2019-01-25 2023-07-25 上海鲸舟基因科技有限公司 基于全转录组的肿瘤抗原预测方法及其应用
WO2020157760A1 (en) * 2019-01-31 2020-08-06 Bar Ilan University Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy
JP7492524B2 (ja) * 2019-02-11 2024-05-29 フラッグシップ・パイオニアリング・イノベーションズ・ブイアイ，エルエルシー 機械学習支援ポリペプチド解析
EP3927354A1 (en) 2019-02-20 2021-12-29 Rubius Therapeutics, Inc. Engineered erythroid cells including loadable antigen-presenting polypeptides and methods of use
CN111621564B (zh) * 2019-02-28 2022-03-25 武汉大学 一种鉴定有效肿瘤新抗原的方法
CN113711239A (zh) * 2019-03-06 2021-11-26 磨石生物公司 利用ii类mhc模型鉴别新抗原
JP7665205B2 (ja) 2019-03-11 2025-04-21 エヴァクシオン・バイオテック・アクティエセルスカブ ネオエピトープをコードするコンストラクトを用いた核酸ワクチン接種
US12427195B1 (en) * 2019-03-11 2025-09-30 La Jolla Institute For Immunology Methods of neoantigen identification
CN111696628A (zh) * 2019-03-15 2020-09-22 痕准生物科技有限公司 新生抗原的鉴定方法
US11599774B2 (en) * 2019-03-29 2023-03-07 International Business Machines Corporation Training machine learning model
CN110172513A (zh) * 2019-05-30 2019-08-27 浙江自贸区锐赛生物医药科技有限公司 突变型免疫多肽临床入组的筛选方法
WO2020243719A1 (en) 2019-05-30 2020-12-03 Gritstone Oncology, Inc. Modified adenoviruses
WO2021003348A1 (en) * 2019-07-02 2021-01-07 Gritstone Oncology, Inc. Hiv antigens and mhc complexes
CN120775062A (zh) 2019-07-16 2025-10-14 吉利德科学公司 Hiv疫苗及其制备和使用方法
US20220334129A1 (en) 2019-09-13 2022-10-20 Evaxion Biotech A/S Method for identifying T-cell epitopes
CN110706747B (zh) * 2019-09-17 2021-09-07 北京橡鑫生物科技有限公司 检测肿瘤新生抗原多肽的方法和装置
CN110456079B (zh) * 2019-09-20 2020-06-02 四川大学华西医院 Tapbp自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
US12394502B2 (en) * 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
JP7470787B2 (ja) 2019-11-05 2024-04-18 パーソナリス，インコーポレイティド 単一試料からの腫瘍純度の推定
WO2021123232A1 (en) 2019-12-18 2021-06-24 Evaxion Biotech Aps Nucleic acid vaccination using neo-epitope encoding constructs
EP4116436A4 (en) * 2020-01-07 2024-01-31 Korea Advanced Institute of Science and Technology METHOD AND SYSTEM FOR SCREENING NEOANTIGENS AND USES THEREOF
CN111303268B (zh) * 2020-03-10 2021-08-27 江苏兰恩生物治疗技术研究院有限公司 子宫肌瘤新抗原、其应用和子宫肌瘤疫苗
CA3174417A1 (en) 2020-04-07 2021-10-14 Birgitte Rono Neoepitope immunotherapy with apc targeting unit
US11920202B2 (en) 2020-04-09 2024-03-05 University Of Connecticut Unbiased identification of tumor rejection mediating neoepitopes
EP4143830A1 (en) * 2020-04-27 2023-03-08 Flagship Pioneering Innovations VI, LLC Optimizing proteins using model based optimizations
WO2021236854A1 (en) * 2020-05-19 2021-11-25 Gritstone Bio, Inc. Sars-cov-2 vaccines
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
JP2023534220A (ja) 2020-07-14 2023-08-08 マイネオ エヌブイ 新生抗原の提示尤度を決定するための方法、システム及びコンピュータプログラム製品
JP2023533871A (ja) 2020-07-14 2023-08-04 エヴァクシオン・バイオテック・アクティエセルスカブ 免疫療法のためのａｐｃ標的化単位
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒
MX2023001596A (es) 2020-08-07 2023-04-20 Neogene Therapeutics B V Métodos para enriquecer células t diseñadas genéticamente.
US20220139498A1 (en) * 2020-11-04 2022-05-05 Basf Corporation Apparatuses, systems, and methods for extracting meaning from dna sequence data using natural language processing (nlp)
WO2022098936A1 (en) * 2020-11-06 2022-05-12 Amazon Technologies, Inc. Selecting neoantigens for personalized cancer vaccine
US12053517B2 (en) 2021-01-14 2024-08-06 Gilead Sciences, Inc. HIV vaccines and methods of using
WO2022159176A1 (en) * 2021-01-19 2022-07-28 Amazon Technologies, Inc. A deep learning model for predicting tumor-specific neoantigen mhc class i or class ii immunogenicity
US20220319635A1 (en) * 2021-04-05 2022-10-06 Nec Laboratories America, Inc. Generating minority-class examples for training data
CN113129998B (zh) * 2021-04-23 2022-06-21 云测智能科技有限公司 临床个体化肿瘤新抗原的预测模型构建方法
EP4329780B1 (en) 2021-04-29 2025-11-26 Yeda Research and Development Co. Ltd T cell receptors directed against ras-derived recurrent neoantigens and methods of identifying same
BR112023022485A2 (pt) 2021-04-30 2024-01-09 Centre Hospitalier Univ Vaudois Chuv Expansão de linfócitos em um único recipiente
WO2022251034A1 (en) * 2021-05-27 2022-12-01 Amazon Technologies, Inc. Multicomponent chemical composition of a peptide-based neoantigen vaccine
EP4413580A4 (en) 2021-10-05 2025-08-13 Personalis Inc PERSONALIZED TESTS FOR PERSONALIZED CANCER MONITORING
CN113807468B (zh) * 2021-10-15 2022-05-27 南京澄实生物科技有限公司 基于多模态深度编码的hla抗原呈递预测方法和系统
CN113762416B (zh) * 2021-10-15 2023-05-30 南京澄实生物科技有限公司 基于多模态深度编码的抗原免疫原性预测方法和系统
JP2025509607A (ja) 2022-03-14 2025-04-11 ジェネレーション バイオ カンパニー 異種プライムブーストワクチン組成物及び使用の方法
TWI805290B (zh) * 2022-03-28 2023-06-11 臺北醫學大學 用於預測肺腺癌是否具有表皮生長因子受體突變的方法
US20230368872A1 (en) * 2022-05-16 2023-11-16 Spencer Health Solutions, Llc Alert decision support system based on patient quality of life survey information and related methods and computer program products
KR20250144510A (ko) 2022-11-02 2025-10-10 티젠 파마 에스에이 림프구 확장
WO2024261339A1 (en) 2023-06-23 2024-12-26 Tigen Pharma Sa Lymphocyte-stimulatory matrix (lsm) and uses thereof for expansion of lymphocyte populations
US20250140344A1 (en) 2023-10-31 2025-05-01 Tempus Ai, Inc. T cell receptor screening methods
WO2025137574A1 (en) * 2023-12-21 2025-06-26 Moonshot Antibodies, Llc Methods for treatment of cancer with polynucleotides or antibodies that target mutated cell surface related proteins
CN118351934B (zh) * 2024-04-26 2025-01-28 广州润生细胞医药科技有限责任公司 一种基于二代测序数据的肿瘤新抗原识别方法及系统
CN118314949B (zh) * 2024-04-26 2024-12-13 海南大学 一种抗癌肽预测方法及相关装置
CN119446264B (zh) * 2025-01-09 2025-05-06 天津市肿瘤医院空港医院 一种恶性实体肿瘤的新抗原预测方法及系统
CN120708721A (zh) * 2025-08-15 2025-09-26 北京悦康科创医药科技股份有限公司 一种肿瘤新抗原筛选方法、装置、设备、存储介质及产品

Family Cites Families (238)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
ATE114507T1 (de) 1988-12-28 1994-12-15 Stefan Miltenyi Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5581080A (en) 1989-05-19 1996-12-03 Fenn; John B. Method for determining molecular weight using multiply charged ions
AU5815590A (en) 1989-05-19 1990-12-18 John B. Fenn Multiply charged ions and a method for determining the molecular weight of large molecules
US5130538A (en) 1989-05-19 1992-07-14 John B. Fenn Method of producing multiply charged ions and for determining molecular weights of molecules by use of the multiply charged ions of molecules
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
JP3056782B2 (ja) 1989-11-03 2000-06-26 ヴァンダービルト ユニバーシティ 標的器官内での遺伝子の発現用医薬組成物
AU7492291A (en) 1990-02-26 1991-09-18 Board Of Trustees Of The Leland Stanford Junior University Identification and expression of insect steroid receptor dna sequences
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
WO1993024640A2 (en) 1992-06-04 1993-12-09 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
DE4444229C2 (de) 1994-03-10 1996-07-25 Bruker Franzen Analytik Gmbh Verfahren und Vorrichtungen zur Elektrosprüh-Ionisierung für speichernde Massenspektometer
US5608217A (en) 1994-03-10 1997-03-04 Bruker-Franzen Analytik Gmbh Electrospraying method for mass spectrometric analysis
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
WO1999019484A1 (en) 1997-10-10 1999-04-22 Basf Aktiengesellschaft T cell receptor-associated molecules (trams) and methods of use therefor
DE19937828C1 (de) 1999-08-11 2000-10-05 Smb Schwede Maschinenbau Gmbh Schweißkopf für eine Bandumreifungsmaschine
WO2001025268A1 (en) 1999-10-04 2001-04-12 Schrotz King Petra Human seizure related proteins
DE60122685T2 (de) 2000-03-22 2007-08-23 Rheogene Holdings Inc. Induziertes genexpressionssystem basierend auf ecdysonrezeptoren
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
WO2001074859A2 (en) * 2000-04-04 2001-10-11 University Of Rochester A gene differentially expressed in breast and bladder cancer and encoded polypeptides
CA2411126A1 (en) 2000-06-09 2001-12-13 Mds Proteomics, Inc. Labeling of proteomic samples during proteolysis for quantitation and sample multiplexing
GB0018901D0 (en) * 2000-08-03 2000-09-20 Biovation Ltd Peptides presented by cells
US20020192708A1 (en) 2000-10-25 2002-12-19 Hanno Steen Detection of modified amino acids by mass spectrometry
WO2002051438A2 (en) 2000-12-22 2002-07-04 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Use of repulsive guidance molecule (rgm) and its modulators
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
EP1419518A2 (en) 2001-04-09 2004-05-19 MDS Proteomics Inc. Methods and systems for searching genomic databases
US7731648B2 (en) 2001-07-25 2010-06-08 Aduro Biotech Magnetic nanoscale particle compositions, and therapeutic methods related thereto
WO2003038055A2 (en) 2001-10-31 2003-05-08 Mds Proteomics, Inc. Proteins involved in regulation of adipocytes and uses related thereto
DE10211088A1 (de) 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US8053552B2 (en) 2002-04-18 2011-11-08 Mtm Laboratories, Ag Neopeptides and methods useful for detection and treatment of cancer
US20050221350A1 (en) 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
US7176022B2 (en) 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products
DK1592441T3 (da) 2003-02-06 2012-05-14 Aduro Biotech Listeria, hvis indtrængen i ikke-phagocytiske celler er svækket, vacciner omfattende listeria og fremgangsmåder til anvendelse deraf
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
WO2004084936A2 (en) 2003-02-06 2004-10-07 Cerus Corporation Modified free-living microbes, vaccine compositions and methods of use thereof
CA2517396A1 (en) 2003-02-28 2005-03-10 Antigenics Inc. Use of lectins to promote oligomerization of glycoproteins and antigenic molecules
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
DE10341812A1 (de) 2003-09-10 2005-04-07 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
MXPA06007144A (es) 2003-12-24 2007-01-31 Cerus Corp Moleculas de acido nucleico recombinante que codifican proteinas de fusion que comprenden polipeptidos de senal secretoria bacterial y de antigenos, casetes de expresion y bacterias, y metodos para usar las mismas.
DE102004023187A1 (de) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
US20070265818A1 (en) 2004-08-24 2007-11-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems for heightening cell-mediated immune response
US20060095241A1 (en) 2004-10-29 2006-05-04 Microsoft Corporation Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
US7220549B2 (en) 2004-12-30 2007-05-22 Helicos Biosciences Corporation Stabilizing a nucleic acid for nucleic acid sequencing
US7283337B2 (en) 2005-03-04 2007-10-16 Headway Technologies, Inc. Abutted exchange bias design for sensor stabilization
DE102005013846A1 (de) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
EP1806359B1 (en) 2005-09-05 2010-03-17 Immatics Biotechnologies GmbH Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
CA2651796A1 (en) 2006-02-27 2007-09-07 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
JP5347135B2 (ja) 2006-03-01 2013-11-20 アドゥロ バイオテック 遺伝子工学操作されたｌｉｓｔｅｒｉａおよびその使用方法
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
DE102006032362A1 (de) 2006-07-13 2008-01-17 Khd Humboldt Wedag Gmbh Rollenpresse insbesondere zur Gutbettzerkleinerung
US8926993B2 (en) 2006-07-17 2015-01-06 Aduro Biotech Methods and compositions using Listeria for enhancing immunogenicity by prime boost
US8121797B2 (en) 2007-01-12 2012-02-21 Microsoft Corporation T-cell epitope prediction
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
MX2010001086A (es) 2007-07-27 2010-04-09 Immatics Biotechnologies Gmbh Nueva inmunoterapia contra tumores neuronales y cerebrales.
UA103882C2 (uk) 2007-07-27 2013-12-10 Імматікс Біотекнолоджіс Гмбх Композиція пухлино-асоційованих пептидів та відповідна протиракова вакцина
EA018456B1 (ru) 2007-07-27 2013-08-30 Имматикс Байотекнолоджиз Гмбх Новые иммуногенные эпитопы для иммунотерапии
US20100286070A1 (en) 2007-09-14 2010-11-11 Gert Verheyden Affinity tag
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
JP5456689B2 (ja) 2007-12-07 2014-04-02 ミルテンイ バイオテック ゲーエムベーハー 試料を少なくとも２つの成分に分離する遠心分離機
EP2091046A1 (en) 2008-02-15 2009-08-19 Thomson Licensing Presentation system and method for controlling the same
PT2113253E (pt) 2008-04-30 2010-06-15 Immatics Biotechnologies Gmbh Formulações novas de peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antígeno leucocitário humano (hla) para vacinas
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
SI2119726T2 (en) 2008-05-14 2018-03-30 Immatics Biotechnologies Gmbh New and powerful Class II MHC peptides derived from survivin and neurocane
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
ES2741730T3 (es) 2008-05-19 2020-02-12 Advaxis Inc Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico
AU2009249273A1 (en) 2008-05-19 2009-11-26 Aduro Biotech Compositions comprising PrfA*mutant listeria and methods of use thereof
US20140234370A1 (en) 2009-11-11 2014-08-21 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US20150366955A9 (en) 2009-11-11 2015-12-24 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US8840881B2 (en) 2008-08-28 2014-09-23 Aduro Gvax Inc. Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer
US8583380B2 (en) 2008-09-05 2013-11-12 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
PT2172211E (pt) 2008-10-01 2015-03-09 Immatics Biotechnologies Gmbh Composição de peptídeos associados a tumores e vacina anti -cancro relacionada para o tratamento de glioblastoma (gbm) e outros tipos de câncer
CA2743229A1 (en) 2008-11-21 2010-05-27 University Of Copenhagen Priming of an immune response
ES2573404T3 (es) 2009-03-02 2016-06-07 Aduro Biotech Holdings, Europe B.V. Anticuerpos contra un ligando inductor de proliferación (APRIL)
CA2754764A1 (en) * 2009-03-10 2010-09-16 Baylor Research Institute Antigen presenting cell targeted cancer vaccines
US20120077696A1 (en) 2009-03-15 2012-03-29 Technion Research And Development Foundation Ltd. Soluble hla complexes for use in disease diagnosis
EP2413953B1 (en) 2009-04-03 2017-11-08 Agenus Inc. Methods for preparing and using multichaperone-antigen complexes
EP2309262A1 (en) 2009-10-06 2011-04-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for quantifying biomolecules
WO2011060260A2 (en) 2009-11-11 2011-05-19 Advaxis Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
WO2011100754A1 (en) 2010-02-15 2011-08-18 The Trustees Of The University Of Pennsylvania Live listeria-based vaccines for central nervous system therapy
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
WO2011143656A2 (en) * 2010-05-14 2011-11-17 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
EP2576791B8 (en) 2010-05-23 2016-12-21 Aduro BioTech, Inc. Methods and compositions using listeria for adjuvant treatment of cancer
US20130259883A1 (en) 2010-05-24 2013-10-03 Phosimmune, Inc. Class i mhc phosphopeptides for cancer immunotherapy and diagnosis
JP6023706B2 (ja) 2010-07-09 2016-11-09 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． Ｃｄ２７に対するアゴニスト抗体
US20130303594A1 (en) 2010-09-14 2013-11-14 Max-Planok-Gesellschaft Zur Forderung Der Wissenschaften E.V. Hot1 and uses thereof
GB201015765D0 (en) 2010-09-21 2010-10-27 Immatics Biotechnologies Gmbh Use of myeloid cell biomarkers for the diagnosis of cancer
JP5981436B2 (ja) 2010-10-01 2016-08-31 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 寄生的に感染している対象におけるワクチン不応答性を反転させるためのリステリアワクチンベクターの使用
ES2684684T3 (es) 2010-11-17 2018-10-04 Aduro Biotech, Inc. Métodos y composiciones para inducir una respuesta inmune al EGFRVIII
GB201021289D0 (en) 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
CA2823621C (en) 2010-12-30 2023-04-25 Foundation Medicine, Inc. Optimization of multigene analysis of tumor samples
EP3332804A1 (en) 2011-03-11 2018-06-13 Advaxis, Inc. Listeria-based adjuvants
EP2508537A1 (en) 2011-04-04 2012-10-10 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quantitative standard for mass spectrometry of proteins
RU2670745C9 (ru) 2011-05-24 2018-12-13 Бионтех Рна Фармасьютикалс Гмбх Индивидуализированные противоопухолевые вакцины
EP2607375A1 (en) 2011-12-21 2013-06-26 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Variants of yeast NDI1 gene, and uses thereof in the treatment of disease associated with mitochondrial dysfunction.
EP2825195A4 (en) 2012-03-12 2015-10-07 Advaxis Inc INHIBITION OF SUPPRESSOR CELL FUNCTION AFTER TREATMENT WITH A LISTERIAL VACCINE
WO2013158611A1 (en) 2012-04-16 2013-10-24 Agenus Inc. Methods and compositions for the treatment of glioblastomas
JP2015533473A (ja) 2012-07-12 2015-11-26 ペルシミューン，インコーポレイテッド 個別のがんワクチン及び適応免疫細胞療法
GB2520885A (en) 2012-09-05 2015-06-03 Univ Arizona Methods for discovering therapeutic targets
CN105073776B (zh) 2012-11-13 2019-04-12 拜恩科技股份公司 用于治疗表达紧密连接蛋白的癌症疾病的制剂
EP2925348B1 (en) 2012-11-28 2019-03-06 BioNTech RNA Pharmaceuticals GmbH Individualized vaccines for cancer
WO2014093936A1 (en) 2012-12-13 2014-06-19 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
DK2934749T3 (da) 2012-12-19 2023-02-27 Max Planck Gesellschaft Reaktionsbeholder til prøvefremstilling
AU2013370210B2 (en) 2012-12-27 2018-06-14 Aduro Biotech, Inc. Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof
KR102332790B1 (ko) 2013-02-15 2021-12-01 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 키메라 항원 수용체 및 이의 이용 방법
CA3137846A1 (en) 2013-04-07 2014-10-16 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
JP6453855B2 (ja) 2013-05-18 2019-01-16 アドゥロ バイオテック，インク． 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を活性化するための組成物及び方法
WO2014200912A2 (en) * 2013-06-10 2014-12-18 Iogenetics, Llc Mathematical processes for determination of peptidase cleavage
EP3027203B1 (en) 2013-07-30 2020-07-29 BioNTech SE Tumor antigens for determining cancer therapy
WO2015014869A1 (en) 2013-07-30 2015-02-05 Biontech Ag Tumor antigens for determining cancer therapy
AU2014296887A1 (en) 2013-08-02 2016-01-28 Aduro Biotech Holdings, Europe B.V. Combining CD27 agonists and immune checkpoint inhibition for immune stimulation
TWI777196B (zh) 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（五）
DK2959021T3 (en) 2013-08-19 2018-09-10 Biontech Diagnostics Gmbh METHODS AND KITS FOR MOLECULAR SUBTYPE DETERMINATION OF TUMORS
EP3415639B8 (en) 2013-08-19 2023-07-12 Shuwen Biotech Co., Ltd. Methods and kits for the molecular subtyping of tumors
WO2015030585A2 (en) 2013-08-27 2015-03-05 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Methods for detecting post-translationally modified lysines in a polypeptide
AU2014317009A1 (en) 2013-09-05 2016-03-10 Aduro Biotech Holdings, Europe B.V. CD70-binding peptides and method, process and use relating thereto
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
JP6363179B2 (ja) 2013-09-26 2018-07-25 バイオンテック アーゲー Ｒｎａによるシェルを含む粒子
EP3060679B1 (en) 2013-10-25 2019-06-12 BioNTech Diagnostics GmbH Method and kit for determining whether a subject shows an immune response
WO2015058780A1 (en) 2013-10-25 2015-04-30 Biontech Ag Method and kit for determining whether a subject shows an immune response
SG11201602625YA (en) 2013-11-01 2016-05-30 Pfizer Vectors for expression of prostate-associated antigens
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CN106456724A (zh) * 2013-12-20 2017-02-22 博德研究所 使用新抗原疫苗的联合疗法
SG10201805674YA (en) 2014-01-02 2018-08-30 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy
IL287490B (en) * 2014-01-27 2022-08-01 Molecular Templates Inc Shiga toxin nonvaccine effector subunit-containing polypeptides for mammalian applications
WO2015113576A1 (en) 2014-01-29 2015-08-06 Biontech Ag Peptide mimotopes of claudin 18.2 and uses thereof
EP3099708B1 (en) 2014-01-29 2019-09-04 University Health Network Methods and compositions for producing a cell expressing a t cell receptor
JP2017511796A (ja) 2014-02-18 2017-04-27 アドバクシス， インコーポレイテッド 多標的免疫療法を目的とするバイオマーカー
BR112016019534A2 (pt) 2014-02-25 2017-10-24 Advaxis Inc métodos de tratar o crescimento de um tumor e de suscitar uma resposta imune aprimorada contra o crescimento de tumor
EP3113794A4 (en) 2014-03-05 2017-09-06 Advaxis, Inc. Methods and compositions for increasing a t-effector cell to regulatory t cell ratio
US20150278441A1 (en) * 2014-03-25 2015-10-01 Nec Laboratories America, Inc. High-order semi-Restricted Boltzmann Machines and Deep Models for accurate peptide-MHC binding prediction
WO2015164121A1 (en) 2014-04-24 2015-10-29 Advaxis, Inc. Recombinant listeria vaccine strains and methods of producing the same
GB201408255D0 (en) 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
EP2944955A1 (en) 2014-05-13 2015-11-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Benchmark for LC-MS systems
WO2015172843A1 (en) 2014-05-16 2015-11-19 Biontech Diagnostics Gmbh Methods and kits for the diagnosis of cancer
GB201411037D0 (en) 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
US10000533B2 (en) 2014-06-20 2018-06-19 Immatics Biotechnologies Gmbh Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)
KR20170052569A (ko) 2014-07-18 2017-05-12 어드박시스, 인크. 전립선암 치료용 pd-1 길항제 및 리스테리아 기반 백신의 병용
WO2016011320A1 (en) 2014-07-18 2016-01-21 Advaxis, Inc. Bivalent listeria-based delivery system of heterologous antigens
CA2955432A1 (en) 2014-07-18 2016-01-21 Advaxis, Inc. Listeria-based immunogenic compositions for eliciting anti-tumor responses
CN113791220A (zh) 2014-09-10 2021-12-14 豪夫迈·罗氏有限公司 免疫原性突变体肽筛选平台
AU2015314776A1 (en) 2014-09-14 2017-04-06 Washington University Personalized cancer vaccines and methods therefor
CN107002076B (zh) 2014-09-15 2021-11-23 阿布维特罗有限责任公司 高通量核苷酸文库测序
US10987412B2 (en) 2014-09-17 2021-04-27 The John Hopkins University Reagents and methods for identifying, enriching, and/or expanding antigen-specific T cells
CN105524984B (zh) 2014-09-30 2021-04-13 深圳华大基因科技有限公司 预测新抗原表位的方法及设备
US20170218036A1 (en) 2014-10-03 2017-08-03 Yale University Innate immune system modification for anticancer therapy
WO2016062323A1 (en) 2014-10-20 2016-04-28 Biontech Ag Methods and compositions for diagnosis and treatment of cancer
JP2018500006A (ja) 2014-10-31 2018-01-11 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 改変ｔ細胞における遺伝子発現の改変およびその使用
DE102014116335A1 (de) 2014-11-10 2016-05-12 Thyssenkrupp Ag Verbundwerkstoff, Verbundwerkstoffprodukt, Verfahren zu deren Herstellung und Verwendungen dafür
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
ES3049406T3 (en) 2014-12-19 2025-12-16 Broad Inst Inc Methods for profiling the t-cell-receptor repertoire
MA41218A (fr) 2014-12-19 2017-10-24 Advaxis Inc Combinaison de vaccin à base de listeria comportant des anticorps anti-ox40 ou anti-gitr
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
KR102238326B1 (ko) 2015-01-08 2021-04-12 비온테크 에스이 작용성 tnf 수용체 결합제
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
WO2016126876A2 (en) 2015-02-03 2016-08-11 Advaxis, Inc. Listeria-based adjuvants
US20160220652A1 (en) 2015-02-03 2016-08-04 Advaxis, Inc. Methods of using recombinant listeria vaccine strains in disease immunotherapy
KR20170110716A (ko) 2015-02-09 2017-10-11 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 크로마토그래피 적용에서 스웹 및 데드 볼륨을 최소화하는 수단 및 방법
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
CN107889509B (zh) 2015-02-17 2022-02-11 百欧恩泰诊断有限责任公司 用于膀胱癌分子亚型分型的方法和试剂盒
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
US20160317654A1 (en) 2015-03-09 2016-11-03 Kings College London Combination therapy with rar alpha agonists for enhancing th1 response
WO2016145578A1 (en) 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
GB201504502D0 (en) 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
WO2016154412A2 (en) 2015-03-26 2016-09-29 The Trustees Of The University Of Pennsylvania Combination of a pd-1 antagonist and a listeria based vaccine for treating pancreatic cancer
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
WO2016155809A1 (en) 2015-03-31 2016-10-06 Biontech Rna Pharmaceuticals Gmbh Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell
CA2982543A1 (en) 2015-04-13 2016-10-20 Aduro Biotech, Inc. Immunogenic fusion proteins for the treatment of cancer
CN107750256A (zh) 2015-04-13 2018-03-02 艾杜罗生物科技公司 表皮生长因子受体变体iii‑间皮素融合物及其使用方法
US20180318347A1 (en) 2015-04-22 2018-11-08 Agenus Inc. Methods for treating cancer
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
EP3288581B1 (en) 2015-04-27 2020-11-11 Cancer Research Technology Limited Method for treating cancer
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
HK1250513A1 (zh) 2015-05-07 2018-12-21 阿吉纳斯公司 抗ox40抗体及其使用方法
WO2016180467A1 (en) 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
WO2016183361A1 (en) 2015-05-13 2016-11-17 Advaxis, Inc. Immunogenic listeria-based compositions comprising truncated acta-antigen fusions and methods of use thereof
WO2016183486A1 (en) 2015-05-13 2016-11-17 Agenus Inc. Vaccines for treatment and prevention of cancer
HK1252267A1 (zh) 2015-05-20 2019-05-24 The Broad Institute Inc. 共有的新抗原
US10293637B2 (en) 2015-05-21 2019-05-21 Burley Design Llc Bicycle quick release cam lever with biased closure
CA2987239A1 (en) 2015-05-26 2016-12-01 Advaxis, Inc. Personalized delivery vector-based immunotherapy and uses thereof
CN107849144B (zh) 2015-05-29 2021-09-17 艾吉纳斯公司 抗-ctla-4抗体及其使用方法
GB201510771D0 (en) 2015-06-19 2015-08-05 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer
AU2016281958A1 (en) 2015-06-24 2018-02-15 Advaxis, Inc. Manufacturing device and process for personalized delivery vector-based immunotherapy
GB201511191D0 (en) 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201511792D0 (en) 2015-07-06 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
EP3115369A1 (en) 2015-07-09 2017-01-11 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Peptide purification using mixed-phase solid phase extraction material
GB201512369D0 (en) 2015-07-15 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
WO2017017232A1 (en) 2015-07-29 2017-02-02 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for a sample preparation, especially for mass spectrometry
WO2017024006A1 (en) 2015-08-03 2017-02-09 The Johns Hopkins University Personalized, allogeneic cell therapy of cancer
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
WO2017030956A1 (en) 2015-08-14 2017-02-23 Agenus Inc. Method of inducing a t-cell response to phosphopeptides using nucleic acids encoding phosphopeptide mimetics
GB201515321D0 (en) 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
US20170136108A1 (en) 2015-08-28 2017-05-18 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
WO2017040790A1 (en) 2015-09-01 2017-03-09 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
JP2018530579A (ja) 2015-10-12 2018-10-18 ナントミクス，エルエルシー ウイルス性癌ネオエピトープのための組成物および方法
US10546650B2 (en) * 2015-10-23 2020-01-28 Google Llc Neural network for processing aptamer data
US20170166877A1 (en) 2015-12-14 2017-06-15 Bellicum Pharmaceuticals, Inc. Dual controls for therapeutic cell activation or elimination
CN108601731A (zh) 2015-12-16 2018-09-28 磨石肿瘤生物技术公司 新抗原的鉴别、制造及使用
US10497089B2 (en) * 2016-01-29 2019-12-03 Fotonation Limited Convolutional neural network
US20190346442A1 (en) * 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
MX2019006010A (es) 2016-11-23 2019-12-05 Gritstone Oncology Inc Administracion viral de neoantigenos.
KR20180063481A (ko) 2016-12-02 2018-06-12 주식회사 원소프트다임 체지방을 측정하는 클라우드 기반 휴대용 장치를 이용하여 헬스케어 정보를 제공하는 방법 및 이를 이용하는 장치
EP3600340A4 (en) * 2017-03-31 2021-01-20 ACT Genomics (IP) Co., Ltd. CLASSIFICATION SYSTEM FOR CANCER-SPECIFIC IMMUNOGENIC EPITOPES
US20210113673A1 (en) 2017-04-19 2021-04-22 Gritstone Oncology, Inc. Neoantigen Identification, Manufacture, and Use
SG11201911620PA (en) 2017-06-09 2020-01-30 Gritstone Oncology Inc Neoantigen identification, manufacture, and use
JP7763588B2 (ja) 2017-09-05 2025-11-04 グリットストーン バイオ インコーポレイテッド Ｔ細胞療法用の新生抗原の特定法
CN118888004A (zh) 2017-10-10 2024-11-01 磨石生物公司 使用热点进行的新抗原鉴别
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
WO2019168984A1 (en) 2018-02-27 2019-09-06 Gritstone Oncology, Inc. Neoantigen identification with pan-allele models

Also Published As

Publication number Publication date
AU2016369519A1 (en) 2018-07-12
US10847252B2 (en) 2020-11-24
US20190034585A1 (en) 2019-01-31
EP3389630B1 (en) 2023-11-08
US10847253B2 (en) 2020-11-24
HK1257865A1 (en) 2019-11-01
IL259931B1 (en) 2023-10-01
IL305238B1 (en) 2025-09-01
EP3389630A1 (en) 2018-10-24
ES2970865T3 (es) 2024-05-31
IL259931A (en) 2018-07-31
JP7114477B2 (ja) 2022-08-08
IL322399A (en) 2025-09-01
RU2018124997A (ru) 2020-01-16
IL305238A (en) 2023-10-01
US20170199961A1 (en) 2017-07-13
KR20180107102A (ko) 2018-10-01
BR112018012374A2 (pt) 2018-12-04
PH12018501267A1 (en) 2019-02-11
CN119905147A (zh) 2025-04-29
WO2017106638A1 (en) 2017-06-22
TW201733598A (zh) 2017-10-01
EP3389630A4 (en) 2020-01-01
CN108601731A (zh) 2018-09-28
RU2729116C2 (ru) 2020-08-04
JP2022133271A (ja) 2022-09-13
US20180330055A1 (en) 2018-11-15
CO2018007417A2 (es) 2018-09-28
PE20181535A1 (es) 2018-09-26
EP4299136A3 (en) 2024-02-14
KR102883915B1 (ko) 2025-11-18
US20210098077A1 (en) 2021-04-01
MX2023014124A (es) 2023-12-12
EP4299136A2 (en) 2024-01-03
AU2023204618A1 (en) 2023-08-03
AU2016369519B2 (en) 2023-04-20
US20210166784A1 (en) 2021-06-03
US11183286B2 (en) 2021-11-23
KR20250164855A (ko) 2025-11-25
JP2025065197A (ja) 2025-04-17
CA3008641A1 (en) 2017-06-22
IL259931B2 (en) 2024-02-01
US20190065675A1 (en) 2019-02-28
RU2018124997A3 (es) 2020-05-29
TWI765875B (zh) 2022-06-01
JP2019501967A (ja) 2019-01-24
IL305238B2 (en) 2026-01-01
US20170212984A1 (en) 2017-07-27
SG11201804957VA (en) 2018-07-30
US10055540B2 (en) 2018-08-21

Similar Documents

Publication Publication Date Title
CO2018007417A2 (es) Identificación, fabricación y uso de neoantígeno
CO2019012345A2 (es) Identificación, fabricación y uso de neoantígenos
CO2019013609A2 (es) Vectores de neoantígeno de alfavirus
CY1122803T1 (el) Διαδικασιες γραμμης παραγωγης σπορων και χρησεις αυτων
CY1123119T1 (el) Αντινοηματικο νουκλεϊκο οξυ
EP3558324A4 (en) CYCLIC STING DINUCLEOTID AGONISTS FOR CANCER TREATMENT
IL271389A (en) Targeted non-viral dna insertions
HUE060276T2 (hu) Forrásszínnel kapcsolatos mennyiségi információ üzenetküldés
CO2017004736A2 (es) Péptidos macrociclicos útiles como inmunomoduladores
MX2019006010A (es) Administracion viral de neoantigenos.
EP4218905C0 (en) TEMPERATURE MEASUREMENT IN TUMOR TREATMENT FIELD DISTRIBUTION NETWORKS
EP3325665A4 (en) AMPLIFICATION PROCEDURE FOR NUCLEIC ACID SEQUENCES
PH12016502162A1 (en) Multiplex gene editing in swine
MX2020002831A (es) Metodos y procesos para evaluacion no invasiva de variaciones geneticas.
UY34656A (es) Polimorfos de (s)?2?(1?(9h?purin?6?ilamino)propil)?5?fluor?3?fenilquinazolin?4(3h)?ona, composición y método de preparación
EP3377653A4 (en) PROCESS FOR OBTAINING AND CORRECTING INFORMATION OF BIOLOGICAL SEQUENCES
EP3125757C0 (en) METHOD FOR FOCAL SOURCE IDENTIFICATION
EP3500959C0 (en) TECHNIQUES FOR PROVIDING LOCATION-BASED HEALTH ALERTS BASED ON BIOLOGICAL INDICATORS
MX2017001416A (es) Sales co-formadoras de (2s,3s)-7-fluoro-2-(4-fluorofenil)-3-(1-met il-1h-1,2,4-triazol-5-il)-4-oxo-1,2,3,4-tetrahidroquinolin-5-carb oxilato de metilo y sus metodos de preparacion.
MX2022001801A (es) Secuencias recombinantes de cromosoma b de maiz y sus usos.
MX2024003382A (es) Composiciones y metodos para detectar el adn tumoral circulante.
BR112016026730A2 (pt) métodos de caracterização e tratamento de leucemia mieloide aguda
MX390053B (es) Metodos de evaluacion genomica en ganado.
IL264542A (en) Methods for gynecologic neoplasm diagnosis
EP3958878A4 (en) CONDITIONING METHODS FOR GENE THERAPY